問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
康智雄
下載
2020-08-01 - 2025-04-07
Condition/Disease
Test Drug
Participate Sites8Sites
Recruiting4Sites
Terminated4Sites
2018-06-15 - 2021-06-30
Participate Sites6Sites
Recruiting6Sites
Division of Hematology & Oncology
2025-07-01 - 2029-02-12
Participate Sites2Sites
Recruiting2Sites
2025-08-01 - 2032-12-31
Participate Sites5Sites
Recruiting5Sites
2019-05-19 - 2027-01-25
Participate Sites4Sites
2021-11-01 - 2022-08-29
-
2021-06-01 - 2022-05-30
2020-04-01 - 2024-01-10
Metastatic Castration-resistant Prostate Cancer
OPDIVO (nivolumab) Injection 10mg/mL
全部
